What are DPP-4 inhibitor and biguanide drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DPP-4 inhibitor and biguanide drugs are pharmacologic agents that share a common mechanism (typically targeting DPP-4). 0 are currently marketed, with 3 more in clinical development.

DPP-4 inhibitor and biguanide

0 marketed 3 in Phase 3

This page covers all DPP-4 inhibitor and biguanide drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DPP-4.

Targets

DPP-4

Phase 3 pipeline (3)

Sitagliptin plus metformin · Merck Sharp & Dohme LLC · Diabetes
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, enhancing glucose-dependent insulin secretion, and metformin, a biguanide, decreases hepatic glucose production and increases insulin sensitivity.
Placebo to sitagliptin plus metformin · Merck Sharp & Dohme LLC · Diabetes
Sitagliptin plus metformin works by inhibiting dipeptidyl peptidase-4 (DPP-4) and reducing glucose production in the liver, and increasing insulin secretion.
repaglinide and metformin combination tablet · Novo Nordisk A/S · Diabetes
Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.

Patent intelligence

dpp 4 inhibitor and biguanide patent landscape — aggregated cliff calendar, attackable patents, originator estates